{"id":"ap611074-5-gel","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2109015","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AP611074 is a 5% gel formulation developed by Vaxart for topical application. As a phase 2 candidate, it is intended to modulate immune function at the site of application, potentially enhancing antiviral or anti-tumor immunity through local immune activation.","oneSentence":"AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:28:36.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational immunomodulatory indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT02724254","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-01","conditions":"Condyloma","enrollment":218},{"nctId":"NCT01532102","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts","status":"COMPLETED","sponsor":"Anaconda Pharma","startDate":"2012-02-28","conditions":"Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP611074 5% gel","genericName":"AP611074 5% gel","companyName":"Vaxart","companyId":"vaxart","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin. Used for Investigational immunomodulatory indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}